Jul 1, 2026 · 38m · catalyst
Inside the most sophisticated plan for solar geoengineering
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of Catalyst, Shayle Kann interviews Stardust CEO Yanai Yedvab about the company's engineering of proprietary reflective particles for solar geoengineering. They discuss the technical design, economic feasibility, governance frameworks, and ethical dilemmas of using private-sector innovation to cool the planet.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Shayle holds 21.6% of the talking time here. How this is scored →
speaking balance: gold is Shayle, purple is the guest (3 minute bins)
The guest directly counters the common framing that solar geoengineering research encourages moral hazard by asserting a countervailing moral imperative to ensure future generations have emergency tools.
Hardest push from Shayle ▶ 31:52 Host pushes back on Montreal Protocol analogyThe host pushes back against the guest's optimistic regulatory analogy by noting that the Kyoto Protocol followed the same model but failed to solve climate emissions.
Biggest teaching moment ▶ 12:35 Explaining sulfate testing constraints and clinical methodologyThe guest educates the host on the physics of high natural sulfate background levels in the stratosphere, explaining why small-scale sulfate testing is impossible and requires an alternative particle approach.
Shayle holds their own ▶ 10:42 Host cites historical volcanic analogsThe host displays extensive context by citing historical volcanic events like Mount Pinatubo and Mount Tambora to probe the mechanics of localized vs global stratospheric distribution.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Shayle as informed peer | Guest teaching | Guest disagreement | Shayle pushing back | Why |
|---|---|---|---|---|---|---|
| Commercial Break: Bloom Energy, Engie, Energy Hub | 4 | 5 | 0 | 1 | After an opening sponsor block, the host invites an overview of Stardust's technology. The guest explains how their engineered amorphous silica and core-shell calcite particles overcome the toxicity and stratospheric heating limitations of traditional sulfur. | |
| Injection Strategy and Small-Scale Clinical Trial Methodology | 6 | 6 | 0 | 2 | The host demonstrates domain knowledge by referencing volcanic analogs like Mount Pinatubo and Tambora to question injection distribution. The guest educates the host on why sulfates cannot be tested at small scale due to background noise while their particle allows clinical trial style ramp-ups. | |
| Addressing Environmental Risks and Particle Tracking Systems | 5 | 5 | 0 | 2 | The host presses on the legitimate controversy around ecological side effects, toxicity, and rebound risks. The guest systematically breaks the risk framework into three buckets and details their proprietary particle tagging tracking system. | |
| Commercial Break: Mid-Roll Sponsorships | 5 | 3 | 0 | 1 | Following mid-roll ads, the host drills into the unit economics of cooling. Both agree that at ten billion dollars per half degree Celsius, cost is negligible compared to traditional decarbonization or carbon removal interventions. | |
| Governance, Regulation, and the Montreal Protocol Analogy | 6 | 4 | 1 | 4 | The host probes who gets to govern deployment and challenges the guest's optimistic Montreal Protocol analogy by citing the failure of the Kyoto Protocol. The guest insists that governance must be multilateral and state-led rather than private. | |
| The Moral Hazard vs. Moral Imperative Debate | 5 | 5 | 2 | 3 | The host raises the moral hazard argument that cheap geoengineering creates a disincentive for industrial decarbonization. The guest reframes the issue by balancing moral hazard against the moral imperative of developing safe, tested options for future decision-makers. | |
| The Role of Private Enterprise in Climate Tech | 4 | 4 | 1 | 2 | The host questions why this research is housed in a venture-backed commercial company rather than an academic institution. The guest justifies private enterprise by drawing analogies to biotechnology and vaccine development where scale and talent incentives are essential. |